Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment

To evaluate the role of Inhibin A as bio marker for the number of mature oocytes, compared to Estradiol

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases Urogenital Diseases

Age range

18 year–40 year

Sex eligibility

Female

Study type

Observational

Primary location

IVI Middle East Fertilty Clinic

Abu Dhabi, 60202, United Arab Emirates

About this study

Inhibin A could be an improved biomarker regarding the number of expected mature oocytes compared to estradiol.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients undergoing ovarian stimulation with gonadotropins in either a GnRH-agonist or GnRH-antagonist for IVF treatment due to primary / secondary infertility.

Exclusion criteria

Patients undergoing a modified natural cycle stimulation protocol (Taymour cycle) Patients at risk for development of ovarian hyperstimulation syndrome (OHSS)

Treatment and study plan

Primary outcomes

Number of mature oocytes

Time frame: 1 year

Patients undergoing ovarian stimulation with gonadotropins

Sponsors and collaborators

Lead sponsor

ART Fertility Clinics LLC

Other

Collaborators

Ansh Labs

Registry information

Official study title

Role of Inhibin A as Biomarker for Ovarian Response to Stimulation With Gonadotropins for IVF Treatment

Important dates

Study start: 2018
Primary completion: 2019
Study completion: 2019
First posted: Jul 31, 2018
Registry last updated: Aug 8, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed